Evidence map›Paper›PMID 35071608›Full record

ArticleJournal of immunology research2022

Risk of Multidrug Resistant Bacteria Acquisition in Patients with Declared

Alessio Strazzulla, Maria Concetta Postorino, Nabil Belfeki, Laura Iordache, Astrid de Pontfarcy, Aurelia Pitsch, Pierre Leroy, Sebastien Jochmans, Mehran Monchi, Sylvain Diamantis

Abstract read
In one paragraph

Article in Journal of immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Candent issues in pneumonia. Reflections from the Fifth Annual Meeting of Spanish Experts 2023.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alessio StrazzullaInternal Medicine Unit, Groupe Hospitalier Sud Ile de France, Melun, France.ORCID https://orcid.org/0000-0003-0199-3449
Maria Concetta PostorinoPublic Health Unit, Groupe Hospitalier Sud Ile de France, Melun, France.
Nabil BelfekiInternal Medicine Unit, Groupe Hospitalier Sud Ile de France, Melun, France.
Laura IordacheInternal Medicine Unit, Centre Hospitalier Sud Seine et Marne, Fontainebleau, France.
Astrid de PontfarcyInfectious Diseases Unit, Groupe Hospitalier Sud Ile de France, Melun, France.
Aurelia PitschBiology Laboratory, Groupe Hospitalier Sud Ile de France, Melun, France.
Pierre LeroyPublic Health Unit, Groupe Hospitalier Sud Ile de France, Melun, France.
Sebastien JochmansIntensive Care Unit, Groupe Hospitalier Sud Ile de France, Melun, France.
Mehran MonchiIntensive Care Unit, Groupe Hospitalier Sud Ile de France, Melun, France.
Sylvain DiamantisPublic Health Unit, Groupe Hospitalier Sud Ile de France, Melun, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe risk of extended spectrum MATERIALS AND

methodsThe study included all patients admitted in ICU and receiving antibiotic treatment from January 2007 to December 2018. ESBL bacterial acquisition was the main clinical outcome. Mortality in ICU, multidrug resistant bacterial carriage at admission and discharge were the secondary outcomes.

resultsOverall, 3332 patients were included, 132/3332 (3.9%) were labelled

conclusionsThis study confirms that patients with declared

Indexed as

AdultAnti-Bacterial AgentsBacteriabeta-LactamsCarrier StateDrug Resistance, Multiple, BacterialFemaleHospitalizationHumansHypersensitivityIntensive Care UnitsMaleMethicillin-Resistant Staphylococcus aureusMiddle AgedRetrospective StudiesRisk FactorsAnti-Bacterial Agentsbeta-Lactams

Identifiers

PMID35071608
PMCPMC8769862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.